CSI Market
Sign In | Register

Theseus Pharmaceuticals Inc (THRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access THRX Annual Cash Flow →
The data below summarizes Theseus Pharmaceuticals Inc's cash flow activity from Sep 30 2022 to Sep 30 2023, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-42.90
Depreciation & amortization0.06
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation10.21
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Gain Loss From Change In Fair Value Of Preferred Stock Tranche Rights-
Non Cash Interest Income0.05
Increase Decrease In Operating Lease Liability-0.32
Income taxes0.00
Gain (Loss) on Sale of Securities, Net0.00
Increase (Decrease) in Due from Related Parties, Current, Total0.00
Increase (Decrease) in Accounts Payable-3.66
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.48
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.64
Other Working Capital1.37
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.38
Discontinued operations0.00
Net Cash flow from Operating Activities-39.70
Investing Activities
Capital Expenditures-0.06
Sale of Capital Items0.00
Payments for (Proceeds from) Investments0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments-57.56
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Proceeds from Sale and Collection of Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-57.63
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock49.63
Payments of Distributions to Affiliates0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-94.98
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents94.98
Deferred Financing Costs Included In Accounts Payable-
Deferred Financing Costs Included In Accrued Expenses-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities49.63
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-39.76
Total Cash Flow-47.69
4 historic quarters locked

Sign in to unlock the full Theseus Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Theseus Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001745020-23-000080

Figures are derived from filed reports and may be restated. Historical data is subject to revision.